PropertyValue
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/ns/prov#value
  • purposes, including continuation and completion of our Ampion and Optina clinical trials, submission of a BLA relating to Ampion and a NDA relating to Optina, acquisition of manufacturing equipment and related outfitting in connection with the
http://www.w3.org/ns/prov#wasQuotedFrom
  • sec.gov